Sanofi-Aventis board vacancy
Aventis business development head and board member Thomas Hoefstatter announces plans to resign. He was expected to serve on the 18-member management committee of the newly merged company's board, and would have been one of 10 representatives of Aventis. Sanofi-Aventis says it is too soon to know how it will proceed with the management and board vacancy, but that it will meet its deadline for putting the new operational structure in place by Jan. 1 (1"The Pink Sheet" Aug. 2, 2004, p. 3)...
You may also be interested in...
Sanofi and Aventis will begin integrating management and operations following the Federal Trade Commission's July 28 approval of the merger of the two companies
VMS businesses are deemed essential in Department of Homeland Security guidance that provides as basis for orders by most states and localities across the US. During an AHPA webinar, attorney Trent Norris says the federal government prefers leaving business exemptions to shut-down decisions to the states.
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.